NAUT
Nautilus Biotechnology, Inc.
Biotechnology
Market Cap$366M
5Y Perf.-73.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
NAUT vs SEER
Revenue, margins, valuation, and 5-year total return — side by side.
SEER
Seer, Inc.
Biotechnology
Market Cap$105M
5Y Perf.-96.7%
NAUT vs SEER — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | NAUT | SEER |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $366M | $105M |
| Revenue (TTM) | $0.00 | $16M |
| Net Income (TTM) | $-57M | $-79M |
| Gross Margin | — | 40.7% |
| Operating Margin | — | -5.2% |
| Total Debt | $30M | $26M |
| Cash & Equiv. | $12M | $41M |
NAUT vs SEER — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
NAUT
SEER
| Stock | Dec 20 | May 26 | Return |
|---|---|---|---|
| Nautilus Biotechnol… (NAUT) | 100 | 26.5 | -73.5% |
| Seer, Inc. (SEER) | 100 | 3.3 | -96.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NAUT vs SEER
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: NAUT leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Seer, Inc. is the stronger pick specifically for capital preservation and lower volatility and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
NAUT
Nautilus Biotechnology, Inc.
The Growth Play
NAUT carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- EPS growth 16.1%
- -72.4% 10Y total return vs SEER's -96.7%
- 11.7% revenue growth vs SEER's -8.1%
Best for: growth exposure and long-term compounding
SEER
Seer, Inc.
The Income Pick
SEER is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 0.84
- Lower volatility, beta 0.84, Low D/E 7.9%, current ratio 16.53x
- Beta 0.84, current ratio 16.53x
Best for: income & stability and sleep-well-at-night
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | NAUT | 11.7% revenue growth vs SEER's -8.1% |
| Quality / Margins | NAUT | 4.1% margin vs SEER's -486.0% |
| Stability / Safety | SEER | Beta 0.84 vs NAUT's 1.82, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | NAUT | +311.5% vs SEER's +1.6% |
| Efficiency (ROA) | SEER | -25.7% ROA vs NAUT's -29.2%, ROIC -21.3% vs -26.0% |
NAUT vs SEER — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2023
NAUT vs SEER — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLSEERLAGGINGNAUT
NAUTNautilus Biotechnolog…
1leads
SEERSeer, Inc.
3leads
6 Total Categories
CATEGORYLEADERvs NAUTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
SEER1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
SEER8/8
Total Returns1Y, 3Y, 5Y total returns with dividends
NAUT6/6
Risk & VolatilityBeta, volatility, and downside exposure
SEER2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
SEER leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
SEER and NAUT operate at a comparable scale, with $16M and $0 in trailing revenue.
| Metric | NAUTNautilus Biotechn… | SEERSeer, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $16M |
| EBITDAEarnings before interest/tax | -$58M | -$76M |
| Net IncomeAfter-tax profit | -$57M | -$79M |
| Free Cash FlowCash after capex | -$51M | -$46M |
| Gross MarginGross profit ÷ Revenue | — | +40.7% |
| Operating MarginEBIT ÷ Revenue | — | -5.2% |
| Net MarginNet income ÷ Revenue | — | -4.9% |
| FCF MarginFCF ÷ Revenue | — | -2.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +4.5% |
| EPS Growth (YoY)Latest quarter vs prior year | +7.7% | +8.6% |
SEER leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — NAUT and SEER each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | NAUTNautilus Biotechn… | SEERSeer, Inc. |
|---|---|---|
| Market CapShares × price | $366M | $105M |
| Enterprise ValueMkt cap + debt − cash | $384M | $90M |
| Trailing P/EPrice ÷ TTM EPS | -6.13x | -1.35x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 7.52x |
| Price / BookPrice ÷ Book value/share | 2.32x | 0.36x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — NAUT and SEER each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
SEER leads this category, winning 8 of 8 comparable metrics.
Profitability & Efficiency
SEER delivers a -29.2% return on equity — every $100 of shareholder capital generates $-29 in annual profit, vs $-35 for NAUT. SEER carries lower financial leverage with a 0.08x debt-to-equity ratio, signaling a more conservative balance sheet compared to NAUT's 0.19x. On the Piotroski fundamental quality scale (0–9), SEER scores 4/9 vs NAUT's 1/9, reflecting mixed financial health.
| Metric | NAUTNautilus Biotechn… | SEERSeer, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -35.0% | -29.2% |
| ROA (TTM)Return on assets | -29.2% | -25.7% |
| ROICReturn on invested capital | -26.0% | -21.3% |
| ROCEReturn on capital employed | -32.0% | -25.9% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 4 |
| Debt / EquityFinancial leverage | 0.19x | 0.08x |
| Net DebtTotal debt minus cash | $18M | -$15M |
| Cash & Equiv.Liquid assets | $12M | $41M |
| Total DebtShort + long-term debt | $30M | $26M |
| Interest CoverageEBIT ÷ Interest expense | — | — |
SEER leads this category, winning 8 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
NAUT leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NAUT five years ago would be worth $2,866 today (with dividends reinvested), compared to $494 for SEER. Over the past 12 months, NAUT leads with a +311.5% total return vs SEER's +1.6%. The 3-year compound annual growth rate (CAGR) favors NAUT at 6.6% vs SEER's -19.2% — a key indicator of consistent wealth creation.
| Metric | NAUTNautilus Biotechn… | SEERSeer, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +50.8% | +3.3% |
| 1-Year ReturnPast 12 months | +311.5% | +1.6% |
| 3-Year ReturnCumulative with dividends | +21.0% | -47.2% |
| 5-Year ReturnCumulative with dividends | -71.3% | -95.1% |
| 10-Year ReturnCumulative with dividends | -72.4% | -96.7% |
| CAGR (3Y)Annualised 3-year return | +6.6% | -19.2% |
NAUT leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
SEER leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
SEER is the less volatile stock with a 0.84 beta — it tends to amplify market swings less than NAUT's 1.82 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SEER currently trades 78.0% from its 52-week high vs NAUT's 66.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | NAUTNautilus Biotechn… | SEERSeer, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.82x | 0.84x |
| 52-Week HighHighest price in past year | $4.31 | $2.41 |
| 52-Week LowLowest price in past year | $0.62 | $1.65 |
| % of 52W HighCurrent price vs 52-week peak | +66.8% | +78.0% |
| RSI (14)Momentum oscillator 0–100 | 52.5 | 49.8 |
| Avg Volume (50D)Average daily shares traded | 315K | 401K |
SEER leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates NAUT as "Buy" and SEER as "Hold".
| Metric | NAUTNautilus Biotechn… | SEERSeer, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold |
| Price TargetConsensus 12-month target | $2.50 | — |
| # AnalystsCovering analysts | 5 | 4 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +11.3% |
Insufficient data to determine a leader in this category.
Key Takeaway
SEER leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). NAUT leads in 1 (Total Returns). 1 tied.
Best OverallSeer, Inc. (SEER)Leads 3 of 6 categories
Loading custom metrics...
NAUT vs SEER: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is NAUT or SEER a better buy right now?
Analysts rate Nautilus Biotechnology, Inc.
(NAUT) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — NAUT or SEER?
Over the past 5 years, Nautilus Biotechnology, Inc.
(NAUT) delivered a total return of -71. 3%, compared to -95. 1% for Seer, Inc. (SEER). Over 10 years, the gap is even starker: NAUT returned -72. 4% versus SEER's -96. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — NAUT or SEER?
By beta (market sensitivity over 5 years), Seer, Inc.
(SEER) is the lower-risk stock at 0. 84β versus Nautilus Biotechnology, Inc. 's 1. 82β — meaning NAUT is approximately 116% more volatile than SEER relative to the S&P 500. On balance sheet safety, Seer, Inc. (SEER) carries a lower debt/equity ratio of 8% versus 19% for Nautilus Biotechnology, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — NAUT or SEER?
On earnings-per-share growth, the picture is similar: Nautilus Biotechnology, Inc.
grew EPS 16. 1% year-over-year, compared to -3. 0% for Seer, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — NAUT or SEER?
Nautilus Biotechnology, Inc.
(NAUT) is the more profitable company, earning 0. 0% net margin versus -620. 9% for Seer, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NAUT leads at 0. 0% versus -717. 7% for SEER. At the gross margin level — before operating expenses — SEER leads at 49. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — NAUT or SEER?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is NAUT or SEER better for a retirement portfolio?
For long-horizon retirement investors, Seer, Inc.
(SEER) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 84)). Nautilus Biotechnology, Inc. (NAUT) carries a higher beta of 1. 82 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SEER: -96. 7%, NAUT: -72. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between NAUT and SEER?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.